title: Hepatoblastoma: a single institutional experience of 18 cases.
abstract: Hepatoblastomas are the most common liver tumours in children. However, they are rare as compared to other solid malignancies. Thus, there is a need to integrate data from surgical centers around the world to provide a clearer view on the outcomes of multidisciplinary management of these tumours. We set out to retrospectively review our experience of patients with surgically resected hepatoblastomas looking at primary and secondary outcomes. Children diagnosed with hepatoblastoma and managed surgically (along with chemotherapy) at a single institution between 1 January 2000 and 31 May 2007, were analyzed. Out of the 18 patients, there were 12 male and 6 female patients. The median age was 18 months (range 8-72). A palpable mass in abdomen was the presenting symptom in 88% patients. Sixteen patients (88.8%) underwent major liver resection. Sixteen patients (88.8%) received preoperative chemotherapy. Complete gross resection (stage I and II) was achieved in all 18 patients (100%). The mortality and morbidity rates were 0 and 11.2%, respectively. The 80-month disease-free survival was 67%. This series, the largest from India in terms of surgical resections for hepatoblastoma, reaffirms that major liver resection can be performed with minimal perioperative mortality and morbidity and that the use of chemotherapy has definitely helped in down staging tumours for liver resection.
authors.affiliation: Department of Gastrointestinal Surgical Oncology, Tata Memorial Hospital, Parel, Mumbai 400 012, India. pjshukla@doctors.org.uk
authors.forename: Parul J
authors.initials: PJ
authors.lastname: Shukla
authors.forename: Savio G
authors.initials: SG
authors.lastname: Barreto
authors.forename: Sajid S
authors.initials: SS
authors.lastname: Qureshi
authors.forename: Rohini
authors.initials: R
authors.lastname: Hawaldar
authors.forename: Shailesh V
authors.initials: SV
authors.lastname: Shrikhande
authors.forename: Mukta R
authors.initials: MR
authors.lastname: Ramadwar
authors.forename: Shripad
authors.initials: S
authors.lastname: Banavali
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy / Q000379:methods*; D018197:Hepatoblastoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D006801:Humans; D007223:Infant; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D008297:Male; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents